Literature DB >> 31680380

Clinical, neuroimaging and biochemical findings in patients and patient fibroblasts expressing ten novel GFM1 mutations.

Giulia Barcia1,2, Marlène Rio1,2, Zahra Assouline1,2, Coralie Zangarelli1, Naig Gueguen3, Valerie D Dumas3, Pascale Marcorelles4, Manuel Schiff1,5, Abdelhamid Slama6, Magalie Barth3, Marie Hully7, Pascale de Lonlay8, Arnold Munnich1,2, Isabelle Desguerre7, Jean-Paul Bonnefont1,2, Julie Steffann1,2, Vincent Procaccio3, Nathalie Boddaert9, Agnès Rötig1, Metodi D Metodiev1, Benedetta Ruzzenente1.   

Abstract

Pathogenic GFM1 variants have been linked to neurological phenotypes with or without liver involvement, but only a few cases have been reported in the literature. Here, we report clinical, biochemical, and neuroimaging findings from nine unrelated children carrying GFM1 variants, 10 of which were not previously reported. All patients presented with neurological involvement-mainly axial hypotonia and dystonia during the neonatal period-with five diagnosed with West syndrome; two children had liver involvement with cytolysis episodes or hepatic failure. While two patients died in infancy, six exhibited a stable clinical course. Brain magnetic resonance imaging showed the involvement of basal ganglia, brainstem, and periventricular white matter. Mutant EFG1 and OXPHOS proteins were decreased in patient's fibroblasts consistent with impaired mitochondrial translation. Thus, we expand the genetic spectrum of GFM1-linked disease and provide detailed clinical profiles of the patients that will improve the diagnostic success for other patients carrying GFM1 mutations.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  EFG1; GFM1; OXPHOS; mitochondrial diseases; mitochondrial translation

Mesh:

Substances:

Year:  2019        PMID: 31680380     DOI: 10.1002/humu.23937

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  4 in total

1.  [Analysis of GFM1 gene mutations in a family with combined oxidative phosphorylation deficiency 1].

Authors:  Yaping Shen; Kai Yan; Minyue Dong; Rulai Yang; Xinwen Huang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-10-25

2.  Complementary Transcriptomic and Proteomic Analysis in the Substantia Nigra of Parkinson's Disease.

Authors:  Bao-Hua Dong; Zhao-Qing Niu; Jing-Tao Zhang; Yi-Jing Zhou; Fan-Mei Meng; Ai-Qin Dong
Journal:  Dis Markers       Date:  2021-10-07       Impact factor: 3.434

Review 3.  Mitochondrial Protein Translation: Emerging Roles and Clinical Significance in Disease.

Authors:  Fei Wang; Deyu Zhang; Dejiu Zhang; Peifeng Li; Yanyan Gao
Journal:  Front Cell Dev Biol       Date:  2021-07-01

4.  A novel composition of two heterozygous GFM1 mutations in a Chinese child with epilepsy and mental retardation.

Authors:  Cuiping You; Na Xu; Shiyan Qiu; Yufen Li; Liyun Xu; Xia Li; Li Yang
Journal:  Brain Behav       Date:  2020-08-09       Impact factor: 2.708

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.